Business Context and Reporting Period
This Form 8-K Current Report was filed by TherapeuticsMD, Inc. on May 3, 2018, covering events occurring on May 1, 2018. The filing primarily details the entry into a material definitive credit agreement and references the company's financial results for the first quarter ended March 31, 2018, which were announced via a press release on May 3, 2018.
Key Financial Metrics and Debt Structure
The filing does not provide specific revenue, profit, or cash flow figures for the quarter ended March 31, 2018, as those details are contained in an unfiled press release (Exhibit 99.1). However, the filing outlines a significant new debt facility:
- Total Facility: A secured term loan facility with an aggregate principal amount of up to $200 million.
- Tranche Structure:
- Tranche 1: $75.0 million, available by July 31, 2018, contingent on FDA approval of the TX-004HR New Drug Application (NDA).
- Tranche 2: $75.0 million, available by May 31, 2019, contingent on Tranche 1 funding, FDA approval of TX-001HR, and the first commercial sale of TX-001HR in the U.S.
- Tranche 3: $50.0 million, available by December 31, 2019, contingent on Tranche 2 funding and the generation of at least $75.0 million in consolidated net revenue from TX-001HR and TX-004HR sales in the preceding 12 months.
- Interest Rate: One-month LIBOR (with a 1.50% floor) plus 7.75% per annum.
- Repayment Terms: Principal payable in 36 equal monthly installments beginning May 1, 2020, maturing May 1, 2023. An interest-only extension to May 1, 2021, is possible if $95.0 million in revenue is generated by December 31, 2019.
- Fees: 1.00% origination fee on the maximum potential amount; annual administration fees apply.
- Prepayment Penalties: 4.0% in year one, 3.0% in year two, and 2.0% thereafter.
Material Changes and Covenants
The primary material change is the execution of the Credit Agreement, creating a direct financial obligation secured by a first-priority lien on all existing and after-acquired assets of the Borrowers. The agreement imposes strict covenants, including:
- Liquidity Covenant: Maintenance of a minimum cash balance of $50.0 million.
- Revenue Covenant: Achievement of certain minimum consolidated net revenue amounts from commercial product sales.
- Restrictions: Limitations on incurring additional indebtedness, liens, paying dividends, selling assets, and entering into affiliate transactions.
Guidance, Risks, and Contingencies
The filing highlights significant contingencies tied to the debt facility's drawdown and repayment flexibility:
- Regulatory Risk: Access to the first $150 million of the loan facility is contingent upon FDA approvals for drug candidates TX-004HR and TX-001HR.
- Commercial Risk: Access to the final $50 million tranche and the option to extend the interest-only period depend on achieving specific commercial revenue milestones ($75.0 million and $95.0 million, respectively).
- Events of Default: Include payment defaults, covenant breaches, material adverse effects, delisting of common stock, bankruptcy, and cross-defaults.
- Forward-Looking Statements: The company disclaims any obligation to update forward-looking statements regarding expectations or changes in circumstances.
Investor Verification Checklist
- Verify the specific Q1 2018 revenue and cash burn figures in the unfiled press release (Exhibit 99.1) referenced in Item 2.02.
- Confirm the current status of the FDA New Drug Applications for TX-004HR and TX-001HR to assess the likelihood of drawing Tranche 1 and Tranche 2.
- Review the full text of the Credit Agreement (to be filed in the Q2 2018 10-Q) for detailed definitions of "Material Adverse Effect" and specific revenue calculation methodologies.
- Assess the company's current cash position against the $50.0 million minimum cash balance covenant.
- Monitor the timeline for the July 31, 2018 deadline for drawing Tranche 1.